Hologic, Inc., (Nasdaq: HOLX) a global leader in women’s health focused on developing innovative medical technologies that effectively detect, diagnose and treat health conditions, today issued the following statement regarding the United States Preventive Services Task Force draft guidelines for cervical cancer screening:

“Today’s recommendations are an important acknowledgement of the role of Pap testing combined with HPV testing, which is the gold standard of care and the most effective method of identifying cervical cancer,” said Jennifer Schneiders, PhD, President, Diagnostic Solutions at Hologic. “Eliminating cervical cancer is within our reach and history has shown us that safeguarding the most comprehensive screening available is critical to that effort.”

Once the leading cause of cancer death in women, cervical cancer mortality rates have plummeted by 70% mainly due to cervical cancer screening.1 Despite this progress, cervical cancer incidence is no longer declining and cases continue to disproportionately impact Black and Hispanic women, making a focus on routine screening and vaccination imperative.2-4

Multiple studies and other research representative of real-world screening practices in the US demonstrate that screening women ages 30-65 with the Pap test combined with HPV test identifies more cervical pre-cancer and cancer than either test used alone.5-8 The draft recommendations reinforce the value of all three cervical cancer screening strategies for women including Pap testing for women ages 21-29 years old.9 The draft recommendations also continue to allow for shared decision-making between healthcare providers and patients and help ensure that women can continue to access the preventive care they need and deserve.

Hologic is committed to working with USPSTF and others within the cervical cancer community in support of final screening guidelines that preserve all screening options, improving our ability to combat this preventable cancer and save more women’s lives.

About Hologic

Hologic, Inc. is a global leader in women’s health dedicated to developing innovative medical technologies that effectively detect, diagnosis and treat health conditions and raise the standard of care around the world. To learn more, visit www.hologic.com and connect with us on LinkedIn, Facebook, X (Twitter), Instagram and YouTube.

SOURCE: Hologic, Inc.

References

  1. American Cancer Society. Cancer Statistics Center. https://cancerstatisticscenter.cancer.org/?_ga=2.150839477.2044751383.1547156654-294386523.1544563210#!/. Accessed December 4, 2024.
  2. Surveillance, Epidemiology, and End Results (SEER) Program. SEER*Stat Database: Incidence - SEER Research Data, 8 Registries, Nov 2023 Sub (1975-2021). Accessed December 4, 2024. https://seer.cancer.gov/statfacts/html/cervix.html
  3. Beavis AL, Gravitt PE. Hysterectomy-corrected cervical cancer mortality rates reveal a larger racial disparity in the United States. Cancer. 2017;123(6):1044-1050.
  4. Office of Minority Health, US Department of Health and Human Services. Cancer and Hispanic Americans. https://minorityhealth.hhs.gov/omh/browse.aspx?lvl=4&lvlid=61. Accessed December 4, 2024.
  5. Austin RM, et al. Enhanced detection of cervical cancer and precancer through use of imaged liquid-based cytology in routine cytology and HPV co-testing. Am J Clin Pathol.2018;150(5):385-392. doi: 10.1093/ajcp/aqy114
  6. Blatt AJ, et al. Comparison of cervical cancer screening results among 256,648 women in multiple clinical practices. Cancer Cytopathol. 2015;123(5):282-288. doi:10.1002/ cncy.21544
  7. Kaufman H, et al. Contributions of Liquid-Based (Papanicolaou) Cytology and Human Papillomavirus Testing in Cotesting for Detection of Cervical Cancer and Precancer in the United States. Am J Clin Pathol. 2020:XX:0-0 DOI: 10.1093/AJCP/AQAA074
  8. Zhou H, et al. Clinical performance of the Food and Drug Administration-Approved high-risk HPV test for the detection of high-grade cervicovaginal lesions. Cancer Cytopathol. 2016 May;124(5):317-23. doi: 10.1002/cncy.21687.
  9. U.S. Preventive Services Task Force. Draft Recommendation Statement. Cervical Cancer Screening. December 10, 2024. https://www.uspreventiveservicestaskforce.org/uspstf/draft-recommendation/cervical-cancer-screening-adults-adolescents

 

Investor Contact Ryan Simon Vice President, Investor Relations +1 858.410.8514 ryan.simon@hologic.com

Media Contact Bridget Perry Senior Director, Corporate Communications +1 508.263.8654 bridget.perry@hologic.com

Hologic (NASDAQ:HOLX)
Gráfico Histórico do Ativo
De Jan 2025 até Fev 2025 Click aqui para mais gráficos Hologic.
Hologic (NASDAQ:HOLX)
Gráfico Histórico do Ativo
De Fev 2024 até Fev 2025 Click aqui para mais gráficos Hologic.